Retreatment with Peptide-Receptor Radionuclide Therapy: Effects on Long-term Survival, Renal and Bone Marrow Toxicity Using Yttrium-90 vs. Lutetium-177 Abstract #1456

Introduction: PRRT is an effective treatment for metastatic NETs. The effect of PRRT retreatment is unknown.
Aim(s): To determine efficacy & toxicity of retreatment with PRRT.
Materials and methods: We reviewed patients retreated with PRRT. Patients included: 2 or more cycles of PRRT and retreated >12mths later. We evaluated PFS and toxicity (renal and BM) after initial and retreatment PRRT. Treatment activities were 3.2GBq/cycle for 90Y- and 7.4GBq/cycle for 177Lu-DOTATATE.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Joseph Machta
Keywords: PRRT, retreatment

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1416 Efficacy of Peptide Receptor Radionuclide Therapy in Patients with Advanced Bronchial Neuroendocrine Tumours
Introduction: There is not established treatment pathway in advanced bronchial neuroendocrine tumours(bNETs).
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Apostolos Koffas
Keywords: PRRT, bronchial NETs
#1814 Predictors of Outcome in Patients Treated with Peptide Radio-Labelled Receptor Target Therapy (PRRT)
Introduction: The efficacy of PRRT has been demonstrated in patients with well differentiated NETS. The NETTER-01 study demonstrated disease stabilisation or partial response in approximately 80% of patients. However, more studies are needed to identify predictors of response
Conference: 14th Annual ENETS conference 2017 (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Georgios Demetriou
Keywords: PRRT, Y90, Lu-177
#1106 Salvage Treatment with Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Advanced VIPomas and Severe Verner-Morrison Syndrome
Introduction: PRRT is an effective treatment option for advanced Neuroendocrine Tumours
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Clinical cases/reports
Presenting Author: Dr Mehmet Yalchin
Keywords: PRRT VIP
#3019 Incomplete Peptide Receptor Radionuclide Therapy Courses - Are We Selecting Our Patients Appropriately?
Introduction: As per recommendations, a Peptide Receptor Radionuclide Therapy (PRRT) with Lu-177 DOTATATE course usually consists of 4 cycles. Patients may discontinue a PRRT course early, either due to progression or toxicity. Limited data are available about predictive factors for PRRT early discontinuation.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr Julian Gertner
Authors: Gertner J, Groves J, Aziz B, Miah L, ...
Keywords: prrt
#941 Comparison of Radiolableled Somatostatin Analogues and (131) I-MIBG Treatment for the Management of Patients with Metastatic/Progressive Phaeochromocytomas and Paragangliomas
Introduction: Radionuclide therapy has been used to treat patients with progressive/metastatic paragangliomas (PGGs) and pheochromocytomas (PCCs). To date, there is no study comparing (131)I-MIBG and peptide receptor radionuclide treatment (PRRT) in those patients.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Christos Toumpanakis